In this interview we caught up with Jian Guo (University of British Columbia, Vancouver, Canada) to discuss his presentation at ASMS 2020 Reboot. Jian discusses his research inspirations, current focus and what inspired his presentation exploring which data acquisition modes to use for LC–MS-based untargeted metabolomics. Make sure you don’t miss Jian’s presentation, ‘Comparison of three common data acquisition modes…
Read More
Clinical trials are underway for a new COVID-19 treatment that’s delivered by nasal spray. It’s called Sanotize, and it uses a known anti-microbial called nitric oxide. “You’re using a hand sanitizer to disinfect your hands. It’s a similar idea, but instead of a hand sanitizer, it’s a nasal spray to disinfect your upper airway,” said Sanotize CEO Dr. Gilly Regev.…
Read More

UBC Recruits New Faculty Member Dr. Anna Blakney

The Michael Smith Laboratories and School of Biomedical Medical Engineering are excited to welcome Dr. Anna Blakney to UBC. As a joint faculty member and with her extensive training in biomaterials, drug delivery and immunology, Anna will benefit from, and be a key catalyst for, meaningful collaborations in research and education. She will officially join in January 2021. “I’m delighted to join the Michael Smith Labs…
Read More
Host defense peptides (HDPs), also known as antimicrobial peptides, are naturally occurring polypeptides (~12–50 residues) composed of cationic and hydrophobic amino acids that adopt an amphipathic conformation upon folding usually after contact with membranes. HDPs have a variety of biological activities including immunomodulatory, anti-inflammatory, anti-bacterial, and anti-biofilm functions. Although HDPs have the potential to address the global threat of antibiotic…
Read More
A biotech company partnering with major pharmaceutical players like Lilly on Covid-19 drug development is raising $105 million in funding to ramp up. AbCellera announced on Wednesday that it raised that sum in a Series B funding round led by OrbiMed and DCVC Bio. The investment takes the company’s total funding to about $115 million in its eighth year of…
Read More
Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) submitted an investigational new drug application to the US Food and Drug Administration for the next phase of its multinational study of lead drug NP-120, known as Ifenprodil. The drug, an NMDA receptor antagonist, is a potential therapy for patients with COVID-19, the disease caused by coronavirus. Ifenprodil could reduce the infiltration of neutrophils and…
Read More

Cutting-Edge COVID-19 Research in BC Boosted by Research Funding

The Vancouver Coastal Health Research Institute, along with the VGH & UBC Hospital Foundation, is providing funding for innovative research projects aimed at addressing the evolving health care needs and challenges related to the COVID-19 pandemic. This funding will help accelerate research efforts to proactively respond to the virus in BC through prevention, detection, treatment and management. The COVID-19 Research…
Read More
CanSino Biologics Inc. (CanSinoBIO, HK6185) and Precision NanoSystems (PNI) today announced a co-development agreement of a mRNA lipid nanoparticle (mRNA-LNP) vaccine against COVID-19. The parties will leverage PNI’s proprietary RNA vaccine platform, comprising of lipid nanoparticle delivery system and the NanoAssemblr® manufacturing technology, to rapidly advance a COVID-19 mRNA-LNP vaccine candidate towards human clinical testing and pursuant to regulatory approvals,…
Read More
AbCellera announced today that it has entered into a multi-year strategic research collaboration and license agreement with Eli Lilly and Company (Lilly) on the discovery of antibodies for up to nine Lilly-selected therapeutic targets. Lilly will have the rights to develop and commercialize therapeutic products resulting from the collaboration. AbCellera and Lilly were in discussions about the multi-target agreement in early…
Read More
Challenges in the interpretation of whole-genome sequences leave rare disease cases undiagnosed. Cis-regulatory variants are anticipated to resolve a subset of these cases, but present a difficult problem because of their large numbers, small effect sizes, and tissue-specificity. Advancements in experimental genomics and bioinformatics approaches are rapidly revealing the locations of cis-regulatory regions. At least 46 regulatory disease variants have been reported…
Read More